Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
03
07
2022
received:
21
05
2022
accepted:
17
08
2022
pubmed:
30
8
2022
medline:
30
9
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) is monitored by assessing plasma HCV-RNA load. However, detection of HCV core antigen (HCVcAg) may be an alternative. To evaluate the diagnostic performance of the HCVcAg assay to monitor the efficacy of DAAs in HCV-infected patients METHODS: We performed searches in multiple electronic databases until 6 July 2022, of studies evaluating the HCVcAg detection in plasma or serum compared with the HCV-RNA test (gold standard). We calculated pooled measurement at 2 and 4 weeks of treatment, and at end-of-treatment (EOT), as well as sustained virological response (SVR; 12 weeks after EOT). We selected 16 studies from 2016 to 2022, with 3237 patients and 8958 samples. Overall, the diagnostic performance and clinical utility of the HCVcAg assay were poor at week 2 (sensitivity = 0.40, specificity = 0.96, positive likelihood ratio (PLR) = 9.16, negative likelihood ratio (NLR) = 0.63, and area under the summary receiver operating curve (SROC) = 0.57), fair at week 4 (sensitivity = 0.30, specificity = 0.90, PLR = 3.18, NLR = 0.77, and AUC = 0.79), acceptable at EOT (sensitivity = 0.40, specificity =0.98, PLR = 16.54, NLR = 0.62, and AUC = 0.97) and excellent for SVR (sensitivity = 0.94, specificity = 0.99, PLR = 107.54, NLR = 0.06, and AUC = 0.99). The HCVcAg assay may be helpful for monitoring the efficacy of HCV treatment with DAAs in HCV-infected patients at EOT and for documenting SVR, but not at weeks 2 and 4 of treatment due to poor diagnostic performance.
Sections du résumé
BACKGROUND
Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) is monitored by assessing plasma HCV-RNA load. However, detection of HCV core antigen (HCVcAg) may be an alternative.
AIM
To evaluate the diagnostic performance of the HCVcAg assay to monitor the efficacy of DAAs in HCV-infected patients METHODS: We performed searches in multiple electronic databases until 6 July 2022, of studies evaluating the HCVcAg detection in plasma or serum compared with the HCV-RNA test (gold standard). We calculated pooled measurement at 2 and 4 weeks of treatment, and at end-of-treatment (EOT), as well as sustained virological response (SVR; 12 weeks after EOT).
RESULTS
We selected 16 studies from 2016 to 2022, with 3237 patients and 8958 samples. Overall, the diagnostic performance and clinical utility of the HCVcAg assay were poor at week 2 (sensitivity = 0.40, specificity = 0.96, positive likelihood ratio (PLR) = 9.16, negative likelihood ratio (NLR) = 0.63, and area under the summary receiver operating curve (SROC) = 0.57), fair at week 4 (sensitivity = 0.30, specificity = 0.90, PLR = 3.18, NLR = 0.77, and AUC = 0.79), acceptable at EOT (sensitivity = 0.40, specificity =0.98, PLR = 16.54, NLR = 0.62, and AUC = 0.97) and excellent for SVR (sensitivity = 0.94, specificity = 0.99, PLR = 107.54, NLR = 0.06, and AUC = 0.99).
CONCLUSIONS
The HCVcAg assay may be helpful for monitoring the efficacy of HCV treatment with DAAs in HCV-infected patients at EOT and for documenting SVR, but not at weeks 2 and 4 of treatment due to poor diagnostic performance.
Substances chimiques
Antiviral Agents
0
Hepatitis C Antigens
0
RNA, Viral
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1224-1234Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394(10207):1451-66.
WHO. The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections 2022-2030. 2021. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies/developing-ghss-2022-2030
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170-218.
Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio G, et al. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. Antivir Ther. 2014;19(6):559-67.
Lin SF, Tung SY, Wei KL, Chen CH, Hu TH, Shen CH, et al. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C. PLoS One. 2020;15(3):e0229994.
Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318-27.
Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113-42.
Laperche S, Nübling CM, Stramer SL, Brojer E, Grabarczyk P, Yoshizawa H, et al. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples. Transfusion. 2015;55(10):2489-98.
Aguilera A, Alados JC, Alonso R, Eiros JM, Garcia F. Current position of viral load versus hepatitis C core antigen testing. Enferm Infecc Microbiol Clin (Engl Ed). 2020;38(Suppl 1):12-8.
Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, et al. Hepatitis C Core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016;165(5):345-55.
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. London: Cochrane. 2022. https://training.cochrane.org/handbook-diagnostic-test-accuracy
McInnes MDF, Moher D, Thombs BD, McGrath T, Bossuyt PM, and the PRISMA-DTA Group, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388-96.
QUADAS-2 Bristol Medical School: Population Health Sciences | University of Bristol. https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2/
Takwoingi Y, Dendukuri N, Schiller I, Rücker G, Jones HE, Partlett C, et al. Chapter 11: undertaking meta-analysis. Draft version (13 May 2022) for inclusion. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy version 2. London: Cochrane; 2022. https://training.cochrane.org/11-undertaking-meta-analysis
Dwamena B. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies, statistical software components S456880, Boston College Department of economics. 2007.
Macaskill P, Takwoingi Y, Deeks JJ, Gatsonis C. Chapter 10: understanding meta-analysis draft version (13 May 2022) for inclusion. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy version 2. London: Cochrane; 2022. https://training.cochrane.org/10-understanding-meta-analysis
Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y. Chapter 12: presenting findings. Draft version (13 May 2022) for inclusion. In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editors. Cochrane handbook for systematic reviews of diagnostic test accuracy version 2. London: Cochrane; 2022. https://training.cochrane.org/12-presenting-findings
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
Rousseeuw PJ, Ruts I, Tukey JW. The bagplot: a bivariate boxplot. The American Statistician. 1999;53(4):382-7.
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882-93.
Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Patt Recog. 1997;30:1145-59.
Aghemo A, Degasperi E, de Nicola S, Bono P, Orlandi A, D'Ambrosio R, et al. Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14(9):1331-6.
Alonso R, Perez-Garcia F, Ampuero D, Reigadas E, Bouza E. New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay? Diagn Microbiol Infect Dis. 2017;87(3):243-6.
Arboledas JCA, Guerrero IP, Rodríguez MJB, Martos ET, Pérez AB, León CC, et al. Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals. Diagn Microbiol Infect Dis. 2017;89(1):29-34.
Chevaliez S, Feld J, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen. Antivir Ther. 2018;23(3):211-7.
Kumbhar N, Ramachandran K, Kumar G, Rao Pasupuleti SS, Sharma MK, Gupta E. Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: a study from India. Indian J Med Microbiol. 2021;39(4):462-6.
Loggi E, Galli S, Vitale G, di Donato R, Vukotic R, Grandini E, et al. Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. PLoS ONE. 2017;12(11):e0187755.
Łucejko M, Tomasiewicz K, Olczak A, Tudrujek-Zdunek M, Halota W, Jelski W, et al. Hepatitis C virus core antigen as a possible alternative for evaluation of treatment effectiveness after treatment with direct-acting antivirals. Br J Biomed Sci. 2019;76(4):190-4.
Perez-Garcia A, Aguinaga A, Navascues A, Castilla J, Ezpeleta C. Hepatitis C core antigen: diagnosis and monitoring of patients infected with hepatitis C virus. Int J Infect Dis. 2019;89:131-6.
Rossetti B, Loggi E, Raffaelli CS, Mercinelli S, Gandolfo C, Savellini GG, et al. Hepatitis C virus Core antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era. New Microbiol. 2021;44(2):89-94.
van Tilborg M, al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, et al. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. Lancet Gastroenterol Hepatol. 2018;3(12):856-64.
Mancebo Martínez A, Núñez Serrano P, Fernández de Cañete Camacho JC, Moreno Planas JM. Hepatitis C virus Core antigen as an alternative to RNA in the assessment of response to treatment with direct-acting Oral antivirals. Hepatitis Monthly. 2021;21(9):e118579.
Chayanupatkul M, Chittmittraprap S, Pratedrat P, Chuaypen N, Avihingsanon A, Tangkijvanich P. Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis. Antivir Ther. 2020;25(6):305-14.
Nguyen LT, Gray E, O'Leary A, Carr M, De Gascun CF, Irish Hepatitis CORN. The role of Hepatitis C virus Core antigen testing in the era of direct acting antiviral therapies: what we can learn from the protease inhibitors. PLoS One. 2016;11(10):e0163900.
Ko P-H, Tseng C-W, Tseng K-C, Chen Y-C, Hsu C-S. The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct-acting antivirals. Adv Digest Med. 2022;1-7.
Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, et al. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. J Virol Methods. 2017;245:14-8.
Lucejko M, Flisiak R. Quantitative measurement of HCV core antigen for management of interferon-free therapy in HCV-infected patients. Antivir Ther. 2018;23(2):149-56.
Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen. 2003;10(1):47-51.
Wang Y, Jie W, Ling J, Yuanshuai H. HCV core antigen plays an important role in the fight against HCV as an alternative to HCV-RNA detection. J Clin Lab Anal. 2021;35(6):e23755.
Flores GL, Mota JC, da Silva Andrade LT, Lopes RS, Bastos FI, Villar LM. Performance of HCV antigen testing for the diagnosis and monitoring of antiviral treatment: a systematic review and meta-analysis. Biomed Res Int. 2022;2022:7348755.
Sidharthan S, Kohli A, Sims Z, Nelson A, Osinusi A, Masur H, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis. 2015;60(12):1743-51.
Maasoumy B, Buggisch P, Mauss S, Boeker KHW, Müller T, Günther R, et al. Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver Int. 2018;38(11):1906-10.
Pal V, Ancha N, Mann J, Modi AA. Effect of low positive end of treatment viral load with direct-acting antiviral therapy on sustained virologic response. Can J Gastroenterol Hepatol. 2020;2020:8815829.
Chevaliez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti Infect Ther. 2019;17(5):341-7.
Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol. 2013;58(3):535-40.